Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd)

Biochemical and Biophysical Research Communications

Volumn 379, Issue 3, 2009, Pages 775-779

  Zahedi Avval, Farnaz ^a   Berndt, Carsten ^a   Pramanik, Aladdin ^a   Holmgren, Arne ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Motexafin gadolinium; Ribonucleotide reductase

Indexed keywords

GADOLINIUM TEXAPHYRIN; RIBONUCLEOTIDE REDUCTASE;

ARTICLE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; FLUORESCENCE CORRELATION SPECTROSCOPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HELA CELLS; HUMANS; METALLOPORPHYRINS; MICE; OXIDATIVE STRESS; PROTEIN SUBUNITS; RIBONUCLEOTIDE REDUCTASES;

MAMMALIA;

EID: 58549083985     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.12.128     Document Type: Article

References (37)

1. Nordlund P., and Reichard P. Ribonucleotide reductases. Annu. Rev. Biochem. 75 (2006) 681-706
2. Eklund H., Uhlin U., Farnegardh M., Logan D.T., and Nordlund P. Structure and function of the radical enzyme ribonucleotide reductase. Prog. Biophys. Mol. Biol. 77 (2001) 177-268
3. Reichard P. From RNA to DNA why so many ribonucleotide reductases?. Science 260 (1993) 1773-1777
4. Rofougaran R., Vodnala M., and Hofer A. Enzymatically active mammalian ribonucleotide reductase exists primarily as an alpha6beta2 octamer. J. Biol. Chem. 281 (2006) 27705-27711
5. Lillig C.H., Berndt C., and Holmgren A. Glutaredoxin systems. Biochim. Biophys. Acta 1780 (2008) 1304-1317
6. Lillig C.H., and Holmgren A. Thioredoxin and related molecules-from biology to health and disease. Antioxid. Redox Signal. 9 (2007) 25-47
7. Sjoberg B.M., and Sahlin M. Thiols in redox mechanism of ribonucleotide reductase. Methods Enzymol. 348 (2002) 1-21
8. Weber G. Biochemical strategy of cancer cells and the design of chemotherapy: G.H.A. Clowes memorial lecture. Cancer Res. 43 (1983) 3466-3492
9. Nocentini G. Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy. Crit. Rev. Oncol. Hematol. 22 (1996) 89-126
10. Cory J.G. Ribonucleotide reductase as a chemotherapeutic target. Adv. Enzyme Regul. 27 (1988) 437-455
11. Yarbro J.W. Mechanism of action of hydroxyurea. Semin. Oncol. 19 (1992) 1-10
12. Manegold C. Gemcitabine (Gemzar) in non-small cell lung cancer. Expert Rev. Anticancer Ther. 4 (2004) 345-360
13. Richards G.M., and Mehta M.P. Motexafin gadolinium in the treatment of brain metastases. Expert Opin. Pharmacother. 8 (2007) 351-359
14. Evens A.M., Lecane P., Magda D., Prachand S., Singhal S., Nelson J., Miller R.A., Gartenhaus R.B., and Gordon L.I. Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. Blood 105 (2005) 1265-1273
15. Evens A.M., Balasubramanian L., and Gordon L.I. Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies. Curr. Treat. Options Oncol. 6 (2005) 289-296
16. Forouzannia A., Richards G.M., Khuntia D., and Mehta M.P. Motexafin gadolinium: a novel radiosensitizer for brain tumors. Expert Rev. Anticancer Ther. 7 (2007) 785-794
17. Mehta M.P., Rodrigus P., Terhaard C.H., Rao A., Suh J., Roa W., Souhami L., Bezjak A., Leibenhaut M., Komaki R., Schultz C., Timmerman R., Curran W., Smith J., Phan S.C., Miller R.A., and Renschler M.F. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J. Clin. Oncol. 21 (2003) 2529-2536
18. Meyers C.A., Smith J.A., Bezjak A., Mehta M.P., Liebmann J., Illidge T., Kunkler I., Caudrelier J.M., Eisenberg P.D., Meerwaldt J., Siemers R., Carrie C., Gaspar L.E., Curran W., Phan S.C., Miller R.A., and Renschler M.F. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J. Clin. Oncol. 22 (2004) 157-165
19. Hashemy S.I., Ungerstedt J.S., Zahedi Avval F., and Holmgren A. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J. Biol. Chem. 281 (2006) 10691-10697
20. Rigler R., Mets U., Widengren J., and Kask P. Fluorescence correlation spectroscopy with high count rate and low background: analysis of translational diffusion. Eur. Biophys. J. 22 (1993) 169-175
21. Ren X., Bjornstedt M., Shen B., Ericson M.L., and Holmgren A. Mutagenesis of structural half-cystine residues in human thioredoxin and effects on the regulation of activity by selenodiglutathione. Biochemistry 32 (1993) 9701-9708
22. Johansson C., Lillig C.H., and Holmgren A. Human mitochondrial glutaredoxin reduces S-glutathionylated proteins with high affinity accepting electrons from either glutathione or thioredoxin reductase. J. Biol. Chem. 279 (2004) 7537-7543
23. Davis R., Thelander M., Mann G.J., Behravan G., Soucy F., Beaulieu P., Lavallee P., Graslund A., and Thelander L. Purification, characterization, and localization of subunit interaction area of recombinant mouse ribonucleotide reductase R1 subunit. J. Biol. Chem. 269 (1994) 23171-23176
24. Mann G.J., Graslund A., Ochiai E., Ingemarson R., and Thelander L. Purification and characterization of recombinant mouse and herpes simplex virus ribonucleotide reductase R2 subunit. Biochemistry 30 (1991) 1939-1947
25. Engstrom Y., Eriksson S., Thelander L., and Akerman M. Ribonucleotide reductase from calf thymus. Purification and properties. Biochemistry 18 (1979) 2941-2948
26. Ehrenberg M., and Rigler R. Rotational Brownian motion and fluorescence intensity fluctuation. Chem. Phys. 4 (1974) 390-401
27. Marquardt D.W. An algorithm for least-squares estimation of nonlinear parameters. J. Soc. Ind. Appl. Math. 11 (1963) 431-441
28. Whitfield M.L., Sherlock G., Saldanha A.J., Murray J.I., Ball C.A., Alexander K.E., Matese J.C., Perou C.M., Hurt M.M., Brown P.O., and Botstein D. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol. Biol. Cell 13 (2002) 1977-2000
29. Nyholm S., Thelander L., and Graslund A. Reduction and loss of the iron center in the reaction of the small subunit of mouse ribonucleotide reductase with hydroxyurea. Biochemistry 32 (1993) 11569-11574
30. Magda D., Lepp C., Gerasimchuk N., Lee I., Sessler J.L., Lin A., Biaglow J.E., and Miller R.A. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int. J. Radiat. Oncol. Biol. Phys. 51 (2001) 1025-1036
31. Sahlin M., Sjoberg B.M., Backes G., Loehr T., and Sanders-Loehr J. Activation of the iron-containing B2 protein of ribonucleotide reductase by hydrogen peroxide. Biochem. Biophys. Res. Commun. 167 (1990) 813-818
32. Donnelly E.T., Liu Y., Paul T.K., and Rockwell S. Effects of motexafin gadolinium on DNA damage and X-ray-induced DNA damage repair, as assessed by the Comet assay. Int. J. Radiat. Oncol. Biol. Phys. 62 (2005) 1176-1186
33. Woodburn K.W. Intracellular localization of the radiation enhancer motexafin gadolinium using interferometric Fourier fluorescence microscopy. J. Pharmacol. Exp. Ther. 297 (2001) 888-894
34. Engstrom Y., and Rozell B. Immunocytochemical evidence for the cytoplasmic localization and differential expression during the cell cycle of the M1 and M2 subunits of mammalian ribonucleotide reductase. EMBO J. 7 (1988) 1615-1620
35. Pontarin G., Fijolek A., Pizzo P., Ferraro P., Rampazzo C., Pozzan T., Thelander L., Reichard P.A., and Bianchi V. Ribonucleotide reduction is a cytosolic process in mammalian cells independently of DNA damage. Proc. Natl. Acad. Sci. USA 105 (2008) 17801-17806
36. De Stasio G., Rajesh D., Ford J.M., Daniels M.J., Erhardt R.J., Frazer B.H., Tyliszczak T., Gilles M.K., Conhaim R.L., Howard S.P., Fowler J.F., Esteve F., and Mehta M.P. Motexafin-gadolinium taken up in vitro by at least 90% of glioblastoma cell nuclei. Clin. Cancer Res. 12 (2006) 206-213
37. Wu G.N., Ford J.M., and Alger J.R. MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain. J. Neurooncol. 77 (2006) 95-103